Enhancement of 67Cu-2IT-BAT-LYM-1 therapy in mice with human Burkitt's lymphoma (Raji) using interleukin-2

Cancer

Volumn 80, Issue 12 SUPPL., 1997, Pages 2576-2582

  DeNardo, Gerald L ^a,d   Kukis, David L ^a   DeNardo, Sally J ^a   Shen, Sui ^a   Mausner, Leonard F ^b   O'Donnell, Robert T ^a   Lamborn, Kathleen R ^c   Meyers, Frederick J ^a   Srivastava, Suresh C ^b   Miers, Laird A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BROOKHAVEN NATIONAL LABORATORY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Radiodiagnosis and Therapy   (United States)

Author keywords

Antibody; Copper 67; Immunotherapy; Interleukin 2; Lymphoma; Radiotherapy

Indexed keywords

2 IMINOTHIOLANE; 6 [4 (BROMOACETAMIDO)BENZYL] 1,4,8,11 TETRAAZACYCLOTETRADECANE N,N',N'',N''' TETRAACETIC ACID; ACETAMIDE DERIVATIVE; ANTIBODY CONJUGATE; COPPER 67; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT; RECOMBINANT INTERLEUKIN 2; THIOL DERIVATIVE; UNCLASSIFIED DRUG; COPPER; INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; BURKITT LYMPHOMA; CANCER GRAFT; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG RESPONSE; DRUG SCREENING; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; RAJI CELL; XENOGRAFT; ANIMAL; ARTICLE; CANCER TRANSPLANTATION; HUMAN; MORTALITY; TISSUE DISTRIBUTION;

ANIMALS; BURKITT LYMPHOMA; COPPER RADIOISOTOPES; FEMALE; HUMANS; INTERLEUKIN-2; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0031283141     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971215)80:12+<2576::aid-cncr33>3.0.co;2-7     Document Type: Conference Paper

References (23)

1. 67Cu-2IT-BAT-Lym-1 and opportunities for improvement. In: Cancer therapy with radiolabeled antibodies. Goldenberg DM, editor. Boca Raton, FL: CRC Press, 1995:217-27.
2. 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji). Clin Cancer Res 1997;3: 71-9.
3. DeNardo GL, DeNardo SJ, Meares CF, Kukis D, Diril H, McCall MJ, et al. Pharmacokinetics of copper-67 conjugated Lym-1, a potential therapeutic radioimmunoconjugate, in mice and in patients with lymphoma. Antibiotic Immunoconjug Radiopharmacol 1991;4:777-85.
4. DeNardo GL, DeNardo SJ, Lamborn KR, Van Hoosear K, Kroger LA. Enhancement of tumor uptake of monoclonal antibody in nude mice with PEG IL-2. Antibiotic Immunoconjug Radiopharmacol 1991;4:859-70.
5. Nakamura K, Kubo A. Biodistribution of Iodine-125-labeled monoclonal antibody/interlenkin-2 immunoconjugate in athymic mice bearing human tumor xenografts. Cancer 1997;80:2650-5.
6. Becker JC, Pancook JD, Gillies SD, Mendelsohn J, Reisfeld RA. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc Natl Acad Sci USA 1996;93: 2702-7.
7. Hu P, Hornick JL, Glasky MS, Yun A, Milkie MN, Khawli LA, et al. A chimeric Lym-1/interleukin 2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake. Cancer Res 1996;56:4998-5004.
8. Proleukin, Aldesleukin for injection package insert. Emeryville, CA: Chiron Corporation, May 1994.
9. Lewis JP, DeNardo GL, DeNardo SJ. Radioimmunotherapy of lymphoma: a UC Davis experience. Hybridoma 1995;14: 115-20.
10. Epstein AL, Marder RJ, Winter JN, Stathopoulos E, Chen F-M, Parker JW, et al. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 1990;50:2449-54.
11. McCall MJ, Diril H, Meares CF. Simplified method for conjugating macrocycle bifunctional chelating agents to antibodies via 2-iminothiolane. Bioconjugate Chem 1990;2:222-6.
12. Kukis DL, DeNardo GL, DeNardo SJ, Mirick GR, Miers LA, Greiner DP, et al. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugate. Cancer Res 1995;55:878-84.
13. Meares CF, McCall MJ, Reardan DT, Goodwin DA, Diamanti CI, McTigue M. Conjugation of antibodies with bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem 1984;142:68-78.
14. Kukis DL, Diril H, Greiner DP, DeNardo SJ, DeNardo GL, Salako QA, et al. A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates. Cancer 1994;73:779-86.
15. DeNardo SJ, Zhong G-R, Salako Q, Li M, DeNardo GL, Meares CF. Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice. J Nucl Med 1995;36:829-36.
16. 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res 1992;52:6476-81.
17. Deshpande SV, DeNardo SJ, Meares CF, McCall MJ, Adams GP, Moi MK, et al. Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: labeling and biodistribution in RAJI tumored mice. J Nucl Med 1988;29:217-25.
18. 111In-benzyl-EDTA-monoclonal antibody on hepatic uptake and processing in mice. Cancer Res 1989;49:1707-11.
19. Macklis RM, Beresford BA, Palayoor S, Sweeney S, Humm JL. Cell cycle alterations, apoptosis and response to low-dose-rate radioimmunotherapy in lymphoma cells. Int J Radiat Oncol Biol Phys 1993;27:643-50.
20. Reed JC. Mini-review: cellular mechanisms of disease series, bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
21. Gill I, Agah R, Hu E, Mazumder A. Synergistic antitumor effects of interleukin 2 and the monoclonal antibody Lym-1 against human Burkitt lymphoma cells in vitro and in vivo. Cancer Res 1989;49:5377-9.
22. Chen TT, Tao MH, Levy R. Idiotypecytokine fusion proteins as cancer vaccines. Relative efficacy of IL2, IL4, and granulocyte macrophage colony stimulating factor. J Immunol 1994; 153:4775-87.
23. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966;50:219-44.